Mitochondrial DNA levels in blood and tissue samples from breast cancer patients of different stages

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1339-1344

  Xia, Peng ^a,b,c   Wang, Hui Juan ^b,c   Geng, Ting Ting ^b   Xun, Xiao Jie ^b   Zhou, Wen Jing ^b   Jin, Tian Bo ^b,c   Chen, Chao ^b,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c Miniaturized Detection System   (China)

Author keywords

Blood; Breast cancer; Mitochondrial DNA (mtDNA); Quantitative alterations; Tissue

Indexed keywords

MITOCHONDRIAL DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; FEMALE; GENE DOSAGE; GENETICS; HUMAN; MALE; MIDDLE AGED; MITOCHONDRION; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BREAST NEOPLASMS; DNA, MITOCHONDRIAL; FEMALE; GENE DOSAGE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84896834334     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1339     Document Type: Article

References (38)

1. Barrientos A, Casademont J, Cardellach F, et al (1997). Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res, 52, 284-9.
2. Bewick V, Cheek L, Ball J (2004). Statistics review 10: further nonparametric methods. Crit Care, 8, 196-9.
3. Copeland WC, Wachsman JT, Johnson FM, Penta JS (2002). Mitochondrial DNA alterations in cancer. Cancer Invest, 20, 557-69.
4. Dai JG, Zhang ZY, Liu QX, Min JX (2013). Mitochondrial genome microsatellite instability and copy number alteration in lung carcinomas. Asian Pac J Cancer Prev, 14, 2393-9.
5. Dani MA, Dani SU, Lima SP, et al (2004). Less Deltamt DNA4977 than normal in various types of tumors suggests that cancer cells are essentially free of this mutation. Genet Mol Res, 3, 395-409.
6. Fan AX, Radpour R, Haghighi MM, et al (2009). Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer. J Cancer Res Clin Oncol, 135, 983-9.
7. Fliss MS, Usadel H, Caballero OL, et al (2000). Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science, 287, 2017-9.
8. Gonzalez-Masia JA, Garcia-Olmo D, Garcia-Olmo DC (2013). Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther, 6, 819-32.
9. Hibi K, Nakayama H, Yamazaki T, et al (2001). Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer, 94, 429-31.
10. Jeronimo C, Nomoto S, Caballero OL, et al (2001). Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 20, 5195-8.
11. Jiang WW, Masayesva B, Zahurak M, et al (2005). Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res, 11, 2486-91.
12. Jiang WW, Rosenbaum E, Mambo E, et al (2006). Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res, 12, 1564-9.
13. Jones JB, Song JJ, Hempen PM, et al (2001). Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res, 61, 1299-304.
14. Kohler C, Radpour R, Barekati Z, et al (2009). Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer, 8, 105.
15. Lee HC, Li SH, Lin JC, et al (2004). Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res, 547, 71-8.
16. Mambo E, Chatterjee A, Xing M, et al (2005). Tumor-specific changes in mtDNA content in human cancer. Int J Cancer, 116, 920-4.
17. Mehra N, Penning M, Maas J, et al (2007). Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res, 13, 421-6.
18. Mizumachi T, Muskhelishvili L, Naito A, et al (2008). Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate, 68, 408-17.
19. Morten KJ, Ashley N, Wijburg F, et al (2007). Liver mtDNA content increases during development: a comparison of methods and the importance of age-and tissuespecific controls for the diagnosis of mtDNA depletion. Mitochondrion, 7, 386-95.
20. Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D (2002). Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res, 8, 481-7.
21. Okochi O, Hibi K, Uemura T, et al (2002). Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res, 8, 2875-8.
22. Radpour R, Fan AX, Kohler C, Holzgreve W, Zhong XY (2009). Current understanding of mitochondrial DNA in breast cancer. Breast J, 15, 505-9.
23. Selvanayagam P, Rajaraman S (1996). Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab Invest, 74, 592-9.
24. Shen J, Platek M, Mahasneh A, Ambrosone CB, Zhao H (2010). Mitochondrial copy number and risk of breast cancer: a pilot study. Mitochondrion, 10, 62-8.
25. Thyagarajan B, Wang R, Nelson H, et al (2013). Mitochondrial DNA copy number is associated with breast cancer risk. PLoS One, 8, e65968.
26. Tseng LM, Yin PH, Chi CW, et al (2006). Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer, 45, 629-38.
27. Wang K, Yuan Y, Cho JH, et al (2012). Comparing the MicroRNA spectrum between serum and plasma. PLoS One, 7, e41561.
28. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY (2006). Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer, 95, 1087-91.
29. Wang Y, Liu VW, Xue WC, et al (2005). The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol, 98, 104-10.
30. Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, R245-62.
31. Wu CW, Yin PH, Hung WY, et al (2005). Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer, 44, 19-28.
32. Xia P, An HX, Dang CX, et al (2009a). Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer, 9, 454.
33. Xia P, Radpour R, Zachariah R, et al (2009b). Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCR. Genet Mol Biol, 32, 20-4.
34. Xing J, Chen M, Wood CG, et al (2008). Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst, 100, 1104-12.
35. Yin PH, Lee HC, Chau GY, et al (2004). Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer, 90, 2390-6.
36. Yu M (2011). Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci, 89, 65-71.
37. Yu M, Zhou Y, Shi Y, et al (2007). Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life, 59, 450-7.
38. Zhu W, Qin W, Sauter ER (2004). Large-scale mitochondrial DNA deletion mutations and nuclear genome instability in human breast cancer. Cancer Detect Prev, 28, 119-26.